HEM Pharma Inc. Logo

HEM Pharma Inc.

Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.

376270 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 711호, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HEM Pharma Inc. is a biotechnology company specializing in human microbiome research and technology. The company develops personalized healthcare solutions, probiotics, health functional foods, and Live Biotherapeutic Products (LBPs). Its core competency lies in its proprietary Personalized Microbiome Analysis System (PMAS), a screening platform used to identify and develop customized microbial solutions based on multi-omics and metabolome analysis. HEM Pharma also utilizes its MBR high-concentration fermentation technology for efficient production and offers Contract Development and Manufacturing Organization (CDMO) services through its GMP-certified facilities, supporting the entire lifecycle of microbiome-based products from research to manufacturing.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for HEM Pharma Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-26 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB

Automate Your Workflow. Get a real-time feed of all HEM Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HEM Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.